Want to see SOPH full AI Analyst Report?
SOPH Stock Chart & Stats
$8.65
-$0.33(-5.45%)
At close: 4:00 PM EDT
$8.65
-$0.33(-5.45%)
Day’s Range― - ―
52-Week Range$3.83 - $8.98
Previous CloseN/A
Volume192.98K
Average Volume (3M)695.15K
Market Cap
$625.69M
Enterprise Value$380.21M
Total Cash (Recent Filing)$107.67M
Total Debt (Recent Filing)$61.83M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Nov 03, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding85,127,820
10 Day Avg. Volume635,145
30 Day Avg. Volume695,154
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)6.69
Price to Sales (P/S)4.08
P/FCF Ratio-8.17
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue4.41
Enterprise Value/Gross Profit6.62
Enterprise Value/Ebitda-5.96
Forecast
1Y Price Target
$10.00Price Target Upside15.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.94
Revenue Forecast (FY)$95.25M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthAccelerating revenue and a raised full-year outlook indicate sustained demand for the platform rather than a single-period increase. Continued growth can expand the installed customer base, increase analysis volumes, and improve operating leverage as fixed platform capabilities support more revenue.
Customer RetentionHigh net dollar retention and minimal churn demonstrate that existing customers are expanding usage and remaining with the platform. This recurring engagement improves revenue visibility, strengthens the customer base, and creates a durable foundation for growth through additional applications and testing volume.
Product ExpansionCompanion-diagnostic programs and the proposed AI lab extend SOPHiA’s role beyond routine analytics into regulated products, real-world evidence, and pharma collaboration. These initiatives could broaden commercial reach and create additional strategic demand as programs develop over time.
Bears Say
Persistent Cash BurnSubstantial negative operating and free cash flow shows that the business is not yet self-funding, despite some improvement from prior years. Continued burn can require further financing and limits flexibility to invest in growth, absorb setbacks, or reach profitability without additional execution progress.
Ongoing Operating LossesSOPHiA remains meaningfully loss-making in the current year, so revenue growth has not yet translated into sustainable profitability. The continuing EBITDA deficit leaves operating performance dependent on future margin expansion and raises the importance of achieving management’s projected breakeven trajectory.
Margin PressureLower gross margins indicate that the current growth mix carries greater delivery and infrastructure costs than the prior period. If services, early-stage pharma work, and regional compute expenses remain elevated, revenue growth may produce less incremental contribution and delay operating leverage.
SOPHiA GENETICS News
SOPH FAQ
What was SOPHiA GENETICS’s price range in the past 12 months?
SOPHiA GENETICS lowest stock price was $3.83 and its highest was $8.98 in the past 12 months.
What is SOPHiA GENETICS’s market cap?
SOPHiA GENETICS’s market cap is $625.69M.
When is SOPHiA GENETICS’s upcoming earnings report date?
SOPHiA GENETICS’s upcoming earnings report date is Nov 03, 2026 which is in 8 days.
How were SOPHiA GENETICS’s earnings last quarter?
SOPHiA GENETICS released its earnings results on Aug 04, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.21 by -$0.09.
Is SOPHiA GENETICS overvalued?
According to Wall Street analysts SOPHiA GENETICS’s price is currently Undervalued.
Does SOPHiA GENETICS pay dividends?
SOPHiA GENETICS does not currently pay dividends.
What is SOPHiA GENETICS’s EPS estimate?
SOPHiA GENETICS’s EPS estimate is -0.2.
How many shares outstanding does SOPHiA GENETICS have?
SOPHiA GENETICS has 85,127,820 shares outstanding.
What happened to SOPHiA GENETICS’s price movement after its last earnings report?
SOPHiA GENETICS reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.21. Following the earnings report the stock price went up 20.211%.
Which hedge fund is a major shareholder of SOPHiA GENETICS?
Currently, no hedge funds are holding shares in SOPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SOPHiA GENETICS Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (15.61% Upside)
$10.00 (15.61% Upside)
Blogger Sentiment
Neutral
SOPH Sentiment 67%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 14.9%
Last 30 Days ▲ 14.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.39%
12-Months-Change
Fundamentals
Return on Equity
-136.71%
Trailing 12-Months
Asset Growth
11.68%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
SOPHiA GENETICS
SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe. Founded in 2011, SOPHiA GENETICS S.A. is headquartered in Saint-Sulpice, Switzerland.
SOPH Company Deck
SOPH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive operational and commercial narrative: accelerating top-line growth (27% YoY), record analysis volumes (+22%), exceptional U.S. momentum (U.S. revenue +64%), materially improved adjusted EBITDA (27% improvement) and strategic, value-creating partnerships (AstraZeneca CDx wins and MSK JV MOU). These positives were balanced against margin pressure from growing pharma and services revenue, one-off legal and restructuring costs, an implementation backlog, and the fact the company remains adjusted EBITDA negative for 2026. On balance, the strategic wins, raised guidance, improved operating leverage, and a strengthened cash position outweigh the near-term margin and legal/headcount transition headwinds.View all SOPH earnings summariesSOPH Stock 12 Month Forecast
Average Price Target
$10.00
▲(15.61% Upside)
Technical Analysis
Schrodinger
―
Zhongchao
―
GeneDx Holdings
―
Definitive Healthcare Corp
―
Omada Health, Inc.
―
Ownership Overview
8.77% Insiders
2.04% Mutual Funds
3.84% Other Institutional Investors
85.17% Public Companies and
Individual Investors